Interleukin-6 trans-signalling in chronic inflammation and cancer (Q36460931)

14 August 2017

1 reference

title

Interleukin-6 trans-signalling in chronic inflammation and cancer (English)

1 reference

14 August 2017

0 references

Scheller J

1

1 reference

PubMed ID

16640655

14 August 2017

Ohnesorge N

series ordinal

2

1 reference

PubMed ID

16640655

14 August 2017

Rose-John S

series ordinal

3

1 reference

14 August 2017

1 May 2006

1 reference

Scandinavian Journal of Immunology

14 August 2017

1 reference

14 August 2017

63

1 reference

14 August 2017

321-329

1 reference

14 August 2017

5

1 reference

Gp130 and the interleukin-6 family of cytokines

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Soluble receptors for cytokines and growth factors: generation and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

IL-6 transsignaling: the in vivo consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Maintenance of pluripotency in human embryonic stem cells is STAT3 independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Transcriptional profiling identifies Id2 function in dendritic cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Sympathetic neurons can produce and respond to interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

New perspectives on the design of cytokines and growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The upper cytokine-binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIF receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Analysis of the leukemia inhibitory factor receptor functional domains by chimeric receptors and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Designing cytokine variants by phage-display

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Functionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

InBase: the Intein Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Semisynthesis and application of carboxyfluorescein-labelled biologically active human interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

IL-6 trans-signaling: the heat is on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

No inhibition of IL-27 signaling by soluble gp130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Design of effective immunotherapy for human autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Pathological role of IL-6 in the experimental allergic bronchial asthma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

Involvement of the acute phase protein alpha 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2006.01750.X

10.1111/J.1365-3083.2006.01750.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16640655